Meg Jardine's Publications

About Meg Jardine's Publications

Honorary Professorial Fellow, The George Institute for Global Health
  • Associate Professor, Faculty of Medicine, UNSW Sydney

  • Cardiovascular adaptations associated with exercise in patients on hemodialysis

    Seminars in Dialysis Date published:

  • Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study

    PLOS One Date published:

  • Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis

    Diabetes, Obesity and Metabolism Date published:

  • Burden of Care and Quality of Life Among Caregivers for Adults Receiving Maintenance Dialysis: A Systematic Review

    American Journal of Kidney Diseases Date published:

  • Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study

    BMJ Open Date published:

  • Protocol for the Study of Heart and Renal Protection-Extended Review: Additional 5-Year Follow-up of the Australian, New Zealand, and Malaysian SHARP Cohort

    Canadian Journal of Kidney Health and Disease Date published:

  • Cultivating Innovative Pragmatic Cluster-Randomized Registry Trials Embedded in Hemodialysis Care: Workshop Proceedings From 2018

    Canadian Journal of Kidney Health and Disease Date published:

  • Benefits and harms of oral anticoagulant therapy in chronic kidney disease: a systematic review and meta-analysis

    Annals of Internal Medicine Date published:

  • Randomised controlled trial of the impact of haemodiafiltration on uraemic neuropathy: FINESSE study protocol

    BMJ Open Date published:

  • Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop

    Kidney International Date published:

  • Glucose lowering and the kidney: are all drug classes equal?

    The Lancet Diabetes & Endocrinology Date published:

  • Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function

    Circulation Date published:

  • Canagliflozin and cardiovascular outcomes in patients with chronic kidney disease

    Date published:

  • Canagliflozin and Cardiovascular (CV) Outcomes in Patients with Chronic Kidney Disease

    Diabetes Date published:

  • Cardiovascular Outcomes Reported in Hemodialysis Trials

    Journal of the American College of Cardiology Date published:

  • Renal trials in diabetes need a platform: time for a global approach?

    The Lancet Diabetes & Endocrinology Date published: